Mereo Biopharma Share Discussion Threads

[stopstopgo] 17/5/2020 16:27

Using the same methodology as in post 451

For May 15th :-

VWAP of MREO ADS $1.32
GBP:USD exchange rate 1.21 (at time of posting)

So MREO ADR price in pence = 109.1
Equivalent price per share = 21.82

At End of Trading Bid/Offer was 17.5/19.

So amazingly they were cheaper to buy in the UK!


Oh and dave4545.... Your information is misleading, Do the maths properly or don't bother posting.

[dzygit1980] 16/5/2020 22:23

Personally I can't see laboratories being affected by corona as they should be wearing all possible protection anyway and easily social distance . But it looks like mereo enjoys their time of f at the moment while all others are working without any problems looking for vaccine hopefully they are not take g to big wages they might run out of cash other wise. ;)

[dzygit1980] 16/5/2020 22:08

I am so gutted I should sell my shares on last spike I would get same amount now just over £6k cheaper bought mine for 28p some time ago

[dave4545] 15/5/2020 20:55

Still no weakness on Nasdaq trading around 1.3-1.35 levels

When it was 1.07-1.1 we were 21p bid

So Nasdaq price is 20% higher and we are 15-20% lower

[escapetohome] 15/5/2020 20:17

I had a further top up, now have some 20,000

[dave4545] 15/5/2020 17:25

I added 25k more myself at 17.99p earlier

[mr dexy] 15/5/2020 15:39

Hi all,

Does anyone know when results are due here.... please?

Regards to all


Mr D

[escapetohome] 15/5/2020 12:24

Im currently
holding just over 12,000 shares.

Whats yours?

[escapetohome] 15/5/2020 12:18

Im in

Price| £0.1815

[the stigologist] 15/5/2020 12:14

holding your shrivelled balls you spineless coward ?

[dave4545] 15/5/2020 11:53

Going lower before higher unless they drop a positive Rns

No quote to sell and 18.15p offer now for 150k

I continue to hold

[oapknob1] 15/5/2020 07:53

Form 6k MREO - 28/4/20COVID-19 has created an unprecedented burden on health systems in impacted countries around the world. As a result, clinical centers have diverted resources away from the performance of clinical trials and because of that and the vulnerability of patients in the Company's setrusumab clinical development program for osteogenesis imperfecta (OI) and its Phase 2 alvelestat program for patients with alpha-1 antitrypsin deficiency (AATD), the Company's clinical activities will face some delays. AATD patients, in particular, are at greater risk from COVID-19 given that the condition is a respiratory and lung condition, for this reason, our Phase 2 alvelestat trial will be delayed with topline data now expected in 2021. We are also currently planning to initiate a Phase 3 study in children with OI in late 2020, however, the initiation of the study may also be delayed.As a result of the COVID-19 pandemic and depending on the length of such pandemic, we may experience disruptions that would significantly impact our business including: A delay or interruption in our ability to enroll and treat patients and to obtain data from ongoing clinical trialsA delay in our ability to further recruit patients to our clinical trials and to screen patients for eligibility for our clinical trials;  • Interruption to key clinical trial activities including monitoring of clinical sites, patient visits, inability to follow patients after they have received treatment and patient assessments;  • A delay in our ability to raise further finances to support our business as a result of the impact on investment and stock prices more generally or as a result of a delay in clinical data availability A delay in our ability to close and negotiate third party partnerships or collaborations or to progress third party collaborations already in place;  • Limitations on employee resources as a result of increased sickness, requirement for employees to care for family members or requirement for employees to self-isolate themselves;  • Interruptions and delays in our development programs as a result of the government required "stay at home" guidelines;  • Delay in responses from regulatory authorities in relation to approvals, amendments or other regulatory engagements required for our ongoing development activities; or  • Supply chain interruptions.The COVID-19 pandemic continues to rapidly evolve and the extent to which it may impact our future business is highly uncertain and difficult to predict. In particular it is not currently known how long travel restrictions and social distancing/isolation requirements will continue to apply in the countries in which we operate and the impact on global health systems, financial markets or the economy as a whole is not yet known.

[oapknob1] 15/5/2020 07:44

They are committed to report by 15th June. Hopefully with an update re the stage 3 trial. Patient safety however is far more important than investors wishing to make a quick profit.When the trial does go ahead, hopefully it will be a complete success.And the next, and the next, etc. There are more to come. One getting to market will be a company maker. If you don't want to invest don't. If your not happy just before or just after the Report get out. Take your loss or profit. When a company gets to stage 3 trials, well look at others who have reached that stage.

[swinsco] 14/5/2020 22:02

YasXAppreciate you responding.

[yasx] 14/5/2020 21:51

Swinsco,

Referencing your post 483.

I have not sold a single share and retain my holding in its entirety. My thesis remains unchanged. What you do is a matter for you, but I continue to firmly believe this will re-rate in due course. I have no problem being patient...

[tole] 14/5/2020 14:50

I've also picked up a small amount today but need to research it a little further when I get some time. Any interesting notes or anything floating about so that I can have a read?

[rediffusion] 14/5/2020 12:27

I've taken my first tranche. Will add in the 16s if it continues to dip

[dave4545] 14/5/2020 11:39

Just a overhang Swinsco

Overhangs clear and prices rebound. The nasdaq price remains way higher.

[swinsco] 14/5/2020 11:32

Not looking good here. Yas on Twitter was pumping this like no tomorrow a couple of weeks back... I fell for it.. lol

[dave4545] 14/5/2020 11:07

150k offered 18.5p

smaller 18.4p

Looks like the seller has decided not to wait for dripping them out at a higher price

[the stigologist] 14/5/2020 02:37

?

Financial Highlights

· Cash resources ¹ of £36.1m as at June 30, 2019 (June 30, 2018 £36.9m)

[ember11] 14/5/2020 02:16

Is MPH's cash position circa $8m ($5m from Novartis + $3m from unknown US investor) or they haven't received their money yet?

[dave4545] 13/5/2020 15:49

hmm 19.78p bid online

Then a instant flip a mm drops to 20p offer and it's 19.78p offer

Test it and you can buy 150,000 online in one go.

Clearly a seller, I'm not selling at 19p bid but I'm not that keen to add more
atm either